

Chiesi announces carbon neutral respiratory portfolio

- As a sustainable pharmaceutical company, Chiesi is committed to achieving NetZero greenhouse gas (GHG) emissions by 2035.
- Chiesi is working on the development of a carbon minimal inhaler with a low global warming potential (GWP) propellant, expected by 2025.
- The introduction of the inhaler and its low GWP will help Chiesi's aim to achieve up to a 90% reduction in scope 3 greenhouse gas emissions from the use of sold products by 2035¹.
- As a result, Chiesi's entire UK portfolio of respiratory products is now certified carbon neutral.

Manchester, UK, 14th February 2024 – Chiesi Ltd, the Manchester-based biopharmaceutical company, has today announced a carbon neutral respiratory portfolio. Chiesi has already committed to a series of projects that will lead to a reduction of 90% direct greenhouse gas emissions generated, as well as emissions associated with the purchase of electricity and heat by 2030, compared to 2019.¹ These include initiatives such as:

- a transition to 100% renewable electricity at all Chiesi Group sites,
- progression of the electrification of its car fleet,
- installing technology at manufacturing sites that aims to capture propellant emissions,
- energy efficiency measures.

Another key element of Chiesi's carbon reduction plan is the development of a carbon minimal inhaler with low global warming potential (GWP) propellant, which is expected to reduce scope 1 emissions, linked to production process. This will help Chiesi's aim to achieve up to a 90% reduction in scope 3 greenhouse gas emissions* from the use of sold products by 2035, compared to 2019.¹

The company has purchased and retired** verified carbon removal credits in a reforestation project in India, to compensate for the carbon emissions of Chiesi's entire UK portfolio of respiratory medicines. This means that the most widely prescribed portfolio of respiratory medicines in the UK is now certified as carbon neutral according to the requirements of PAS2060 – the internationally recognised standard for carbon neutrality.

"We at Chiesi could not be prouder of the steps we are taking to take care of people and the planet," said Ralph Blom, General Manager, Chiesi UK and Ireland. "We are committed to achieving NetZero greenhouse gas emissions by 2035 because creating a healthier climate means a healthier world. Through the development of our low global warming potential propellant and our carbon removal initiative, we are well on our way to making our carbon footprint as small as it can be. We will continue our sustainability journey, regularly assessing our progress and championing a more inclusive and sustainable economy."

To find out more about Chiesi UK's approach to sustainable respiratory care, please visit: <https://www.chiesi.uk.com/sustainable-respiratory-care>.

**Scope 1, 2 and 3 emissions can be described as follows:*

- *Scope 1 covers GHG emissions from sources that an organisation owns or controls directly*
- *Scope 2 are GHG emissions that a company causes indirectly and come from where the energy it purchases and uses is produced*
- *Scope 3 are other GHG emissions so those which are a consequence of the activities of the company, but occur from sources not owned or controlled by the company²*

***Retiring a carbon credit means its value of one tonne of CO₂ has been removed from the purchaser's carbon footprint and the credit can no longer be sold or traded.*

###

About Chiesi UK's Reforestation Project

Chiesi UK has purchased and retired carbon removal credits for a reforestation project in India, verified according to the 'Verified Carbon Standard' administered by Verra.³ This initiative ensures that parcels of degraded land, owned by farmers and small families are reforested under the Farm Forestry Scheme. A total of 12,437 parcels of land covering 14.9k hectares will be reforested. The land is owned by more than 12,000 farmers and their families across three states in India. The carbon removal credits purchased and retired compensate for the carbon emissions of the entire UK respiratory portfolio for the 2022 calendar year. The project is verified to be compliant with PAS2060 – the internationally recognised standard for carbon neutrality. This means Chiesi's entire UK portfolio of respiratory medicines is now certified carbon neutral.

About Chiesi Group

Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment.

By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi's commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we're part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit www.chiesi.uk.com.

Media contacts

Donna Caslin, Chiesi UK
Senior PR and Communications Manager
Phone: (+44) 161 488 5555
Email: d.caslin@chiesi.com

Sarah Pollard
M+F Health
Phone: (+44) 793 9002465
Email: sarah.pollard@mandfhealth.com

References

¹ Chiesi. Action over Words. Available at <https://actionoverwords.co.uk>. Last accessed February 2024.

² The Greenhouse Gas Protocol. A Corporate Accounting and Reporting Standard. Revised Edition. Available at <https://ghgprotocol.org/sites/default/files/standards/ghg-protocol-revised.pdf>. Last accessed February 2024.

³ Verra VCS. Available at <https://registry.verra.org/app/projectDetail/VCS/2404>. Last accessed February 2024.